These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

334 related items for PubMed ID: 19825889

  • 1. Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.
    Pascual AM, Téllez N, Boscá I, Mallada J, Belenguer A, Abellán I, Sempere AP, Fernández P, Magraner MJ, Coret F, Sanz MA, Montalbán X, Casanova B.
    Mult Scler; 2009 Nov; 15(11):1303-10. PubMed ID: 19825889
    [Abstract] [Full Text] [Related]

  • 2. Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?
    Ellis R, Boggild M.
    Mult Scler; 2009 Apr; 15(4):505-8. PubMed ID: 19251838
    [Abstract] [Full Text] [Related]

  • 3. Leukaemia due to mitoxantrone.
    Prescrire Int; 2007 Aug; 16(90):153-6. PubMed ID: 17724842
    [Abstract] [Full Text] [Related]

  • 4. Mitoxantrone-related acute leukemia in two MS patients.
    Pielen A, Goffette S, Van Pesch V, Gille M, Sindic CJ.
    Acta Neurol Belg; 2008 Sep; 108(3):99-102. PubMed ID: 19115673
    [Abstract] [Full Text] [Related]

  • 5. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ.
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [Abstract] [Full Text] [Related]

  • 6. Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study.
    Le Page E, Leray E, Edan G, French Mitoxantrone Safety Group.
    Mult Scler; 2011 Jul; 17(7):867-75. PubMed ID: 21325016
    [Abstract] [Full Text] [Related]

  • 7. [Mitoxantrone].
    Pericot I, Montalban X.
    Neurologia; 2003 Jul; 18(6):318-23. PubMed ID: 12838451
    [Abstract] [Full Text] [Related]

  • 8. Therapy-related acute leukaemia with mitoxantrone: four years on, what is the risk and can it be limited?
    Ellis R, Brown S, Boggild M.
    Mult Scler; 2015 Apr; 21(5):642-5. PubMed ID: 25013152
    [Abstract] [Full Text] [Related]

  • 9. Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis.
    Ramkumar B, Chadha MK, Barcos M, Sait SN, Heyman MR, Baer MR.
    Cancer Genet Cytogenet; 2008 Apr 15; 182(2):126-9. PubMed ID: 18406875
    [Abstract] [Full Text] [Related]

  • 10. Therapy-related acute nonlymphoblastic leukemia following mitoxantrone therapy in a patient with multiple sclerosis.
    Sumrall A, Dreiling B.
    J Miss State Med Assoc; 2007 Jul 15; 48(7):206-7. PubMed ID: 17939254
    [Abstract] [Full Text] [Related]

  • 11. Chronic myeloid leukemia associated with mitoxantrone treatment in a patient with MS.
    Sadiq SA, Rammal M, Sara G.
    Mult Scler; 2008 Mar 15; 14(2):272-3. PubMed ID: 17986509
    [Abstract] [Full Text] [Related]

  • 12. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.
    Zipoli V, Portaccio E, Hakiki B, Siracusa G, Sorbi S, Amato MP.
    J Neurol Sci; 2008 Mar 15; 266(1-2):25-30. PubMed ID: 17870094
    [Abstract] [Full Text] [Related]

  • 13. Mitoxantrone-related acute myeloblastic leukaemia in a patient with metastatic hormone-refractory prostate cancer.
    Martinez V, Mir O, Dômont J, Bouscary D, Goldwasser F.
    Anticancer Drugs; 2007 Feb 15; 18(2):233-5. PubMed ID: 17159610
    [Abstract] [Full Text] [Related]

  • 14. Therapy-related acute leukemia in two patients with multiple sclerosis treated with Mitoxantrone.
    Colovic N, Suvajdzic N, Kraguljac Kurtovic N, Djordjevic V, Dencic Fekete M, Drulovic J, Vidovic A, Tomin D.
    Biomed Pharmacother; 2012 Apr 15; 66(3):173-4. PubMed ID: 22440894
    [Abstract] [Full Text] [Related]

  • 15. Acute myeloid leukaemia induced by mitoxantrone in a multiple sclerosis patient.
    Tanasescu R, Debouverie M, Pittion S, Anxionnat R, Vespignani H.
    J Neurol; 2004 Jun 15; 251(6):762-3. PubMed ID: 15311359
    [No Abstract] [Full Text] [Related]

  • 16. [Acute heart failure in a patient treated by mitoxantrone for multiple sclerosis].
    Feuillet L, Guedj E, Eusebio A, Malikova I, Pelletier J, Mundler O, Ali Chérif A, Groupe Français d'Etude de la mitoxantrone.
    Rev Neurol (Paris); 2003 Dec 15; 159(12):1169-72. PubMed ID: 14978418
    [Abstract] [Full Text] [Related]

  • 17. Clinical follow-up of 304 patients with multiple sclerosis three years after mitoxantrone treatment.
    Debouverie M, Taillandier L, Pittion-Vouyovitch S, Louis S, Vespignani H.
    Mult Scler; 2007 Jun 15; 13(5):626-31. PubMed ID: 17548442
    [Abstract] [Full Text] [Related]

  • 18. Mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis.
    Hamzehloo A, Etemadifar M.
    Arch Iran Med; 2006 Apr 15; 9(2):111-4. PubMed ID: 16649351
    [Abstract] [Full Text] [Related]

  • 19. Acute promyelocytic leukemic involvement of the optic nerves following mitoxantrone treatment for multiple sclerosis.
    Ko MW, Tamhankar MA, Volpe NJ, Porter D, McGrath C, Galetta SL.
    J Neurol Sci; 2008 Oct 15; 273(1-2):144-7. PubMed ID: 18687447
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of the myocardial performance index for early detection of mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis.
    Pattoneri P, Pelà G, Montanari E, Pesci I, Moruzzi P, Borghetti A.
    Eur J Echocardiogr; 2007 Mar 15; 8(2):144-50. PubMed ID: 16603413
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.